GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Hold” from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned an average rating of “Hold” from the sixteen research firms that are currently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $3.9808.

GDRX has been the subject of a number of research analyst reports. Citigroup reduced their target price on GoodRx from $4.50 to $3.50 and set a “buy” rating for the company in a report on Tuesday, March 3rd. Bank of America reaffirmed a “reduce” rating on shares of GoodRx in a research report on Monday, January 5th. Wells Fargo & Company reduced their price objective on GoodRx from $7.00 to $3.50 and set an “overweight” rating for the company in a report on Wednesday, March 4th. The Goldman Sachs Group decreased their target price on GoodRx from $4.00 to $2.50 and set a “neutral” rating for the company in a research report on Monday, March 2nd. Finally, Leerink Partners restated an “outperform” rating and set a $3.00 target price on shares of GoodRx in a research note on Thursday, February 26th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC boosted its holdings in GoodRx by 43.6% in the second quarter. Lazard Asset Management LLC now owns 17,142 shares of the company’s stock worth $85,000 after purchasing an additional 5,201 shares during the last quarter. Brevan Howard Capital Management LP grew its position in GoodRx by 7.7% in the 3rd quarter. Brevan Howard Capital Management LP now owns 95,483 shares of the company’s stock worth $404,000 after purchasing an additional 6,842 shares during the period. Hirtle Callaghan & Co LLC raised its stake in GoodRx by 60.3% during the 4th quarter. Hirtle Callaghan & Co LLC now owns 18,261 shares of the company’s stock valued at $49,000 after buying an additional 6,869 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in GoodRx by 202.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 11,327 shares of the company’s stock valued at $56,000 after buying an additional 7,580 shares during the last quarter. Finally, Quarry LP bought a new position in shares of GoodRx during the 3rd quarter valued at $33,000. 63.77% of the stock is owned by hedge funds and other institutional investors.

GoodRx Trading Down 0.9%

NASDAQ:GDRX opened at $2.22 on Tuesday. The stock has a market cap of $753.53 million, a price-to-earnings ratio of 24.67, a PEG ratio of 1.55 and a beta of 1.52. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.78. The company’s 50 day moving average price is $2.40 and its 200-day moving average price is $3.10. GoodRx has a 52 week low of $1.77 and a 52 week high of $5.81.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Wednesday, February 25th. The company reported $0.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.09. The company had revenue of $194.79 million during the quarter, compared to analyst estimates of $193.27 million. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The firm’s revenue for the quarter was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.09 EPS. On average, equities research analysts forecast that GoodRx will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.